Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease.
Journal
International journal of hepatology
ISSN: 2090-3448
Titre abrégé: Int J Hepatol
Pays: United States
ID NLM: 101564967
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
05
2019
revised:
22
12
2019
accepted:
17
01
2020
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
13
2
2020
Statut:
epublish
Résumé
Fecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant We studied the effect of FMT on chronic liver disease (CLD) patients with CDI at our tertiary medical center. A cohort of all patients who received FMT from December 2012 to May 2014 for refractory or recurrent CDI was identified. Patients were monitored for a year after FMT. Descriptive analysis was conducted to compare the effect of FMT in patients with and without CLD. A total of 201 patients with CDI received FMT, 14 of which had a history of CLD. Nine of these patients exhibited cirrhosis of the liver with a mean Child-Turcotte-Pugh score of 8. CDI development in these patients was associated with recent exposure to antibiotics and was observed to be significantly different between both groups (17% of CLD patients vs. 58% in the general cohort, FMT is a safe and effective therapy against CDI for patients with CLD and cirrhosis.
Sections du résumé
BACKGROUND
BACKGROUND
Fecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant
AIMS
OBJECTIVE
We studied the effect of FMT on chronic liver disease (CLD) patients with CDI at our tertiary medical center.
METHODS
METHODS
A cohort of all patients who received FMT from December 2012 to May 2014 for refractory or recurrent CDI was identified. Patients were monitored for a year after FMT. Descriptive analysis was conducted to compare the effect of FMT in patients with and without CLD.
RESULTS
RESULTS
A total of 201 patients with CDI received FMT, 14 of which had a history of CLD. Nine of these patients exhibited cirrhosis of the liver with a mean Child-Turcotte-Pugh score of 8. CDI development in these patients was associated with recent exposure to antibiotics and was observed to be significantly different between both groups (17% of CLD patients vs. 58% in the general cohort,
CONCLUSION
CONCLUSIONS
FMT is a safe and effective therapy against CDI for patients with CLD and cirrhosis.
Identifiants
pubmed: 32047670
doi: 10.1155/2020/1874570
pmc: PMC7007953
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1874570Informations de copyright
Copyright © 2020 Alireza Meighani et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Science. 2013 Sep 6;341(6150):1241214
pubmed: 24009397
Gastroenterol Clin North Am. 2012 Dec;41(4):781-803
pubmed: 23101687
Am J Gastroenterol. 2010 Jan;105(1):106-13
pubmed: 19844204
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499
pubmed: 23439232
Gastroenterology. 2012 Oct;143(4):913-6.e7
pubmed: 22728514
Gastroenterology. 2007 Sep;133(3):818-24
pubmed: 17854593
Hepatology. 2017 Oct;66(4):1354-1355
pubmed: 28714089
Dig Dis Sci. 2017 Apr;62(4):1002-1008
pubmed: 28181098
Gut Microbes. 2017 May 4;8(3):253-267
pubmed: 28609252
Clin Infect Dis. 2007 Aug 1;45(3):302-7
pubmed: 17599306
Am J Gastroenterol. 2014 Jul;109(7):1065-71
pubmed: 24890442
Protein Cell. 2018 May;9(5):462-473
pubmed: 29691757
PLoS One. 2017 Aug 21;12(8):e0182585
pubmed: 28827811
Eur J Gastroenterol Hepatol. 2016 Jul;28(7):826-30
pubmed: 26934528
N Engl J Med. 2019 Nov 21;381(21):2043-2050
pubmed: 31665575
Aliment Pharmacol Ther. 2018 Feb;47(3):371-379
pubmed: 29226561
JAMA. 2019 Jan 15;321(2):156-164
pubmed: 30644982
mBio. 2014 Jun 17;5(3):e00893-14
pubmed: 24939885
Hepatology. 2016 Jan;63(1):339-40
pubmed: 26264779
Am J Transplant. 2014 Aug;14(8):1901-7
pubmed: 24902610
Gastroenterology. 2015 Jul;149(1):223-37
pubmed: 25982290
Science. 1996 Nov 1;274(5288):740-3
pubmed: 8966556
Eur J Gastroenterol Hepatol. 2008 Jun;20(6):512-8
pubmed: 18467910
Dig Dis Sci. 2017 Apr;62(4):1035-1042
pubmed: 28116592
Anaerobe. 2009 Dec;15(6):285-9
pubmed: 19778623
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Liver Transpl. 2012 Aug;18(8):972-8
pubmed: 22505356
Crit Care. 2019 Oct 21;23(1):324
pubmed: 31639033
Am J Gastroenterol. 2019 Jul;114(7):1071-1079
pubmed: 30730351